化合物CUDC-907 T2078
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
2 mg | 1339928-25-4 | ¥421.00 | 询底价 |
25 mg | 1339928-25-4 | ¥1,890.00 | 询底价 |
10 mg | 1339928-25-4 | ¥995.00 | 询底价 |
100 mg | 1339928-25-4 | ¥4,330.00 | 询底价 |
50 mg | 1339928-25-4 | ¥2,930.00 | 询底价 |
5 mg | 1339928-25-4 | ¥638.00 | 询底价 |
1 mL | 1339928-25-4 | ¥673.00 | 询底价 |
1 mg | 1339928-25-4 | ¥297.00 | 询底价 |
500 mg | 1339928-25-4 | ¥8,910.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Fimepinostat
描述: Fimepinostat (CUDC 907) 是一种 I 型PI3K 及 I 和 II 型HDAC 酶抑制剂,作用于 PI3Kα/PI3Kβ/PI3Kδ 和 HDAC1/HDAC2/HDAC3/HDAC10 ,IC50分别为 19/54/39 nM 和 1.7/5.0/1.8/2.8 nM。
细胞实验: CUDC-907 is dissolved in DMSO and stored (-80°C), and then diluted with appropriate medium before use[1]. Human cancer cell lines are plated at densities of 5,000 to 10,000 per well in 96-well flat-bottomed plates with the recommended culture medium. The cells are then incubated with compounds (e.g.,CUDC-907) at various concentrations for 72 hours in culture medium supplemented with 0.5% (v/v) FBS. Growth inhibition is assessed by assay of cellular ATP content using the Perkin-Elmer ATPlite kit[1].
激酶实验: The activities of classes I and II HDACs are measured using the Color-de-Lys assay system. The activity of PI3K is measured using the ADP-Glo luminescent kinase assay. Recombinant PI3K protein, a complex of N-terminal GST-tagged recombinant full-length human p110 and untagged recombinant full-length human p85, is coexpressed in a baculovirus-infected Sf9 cell expression system[1].
体外活性: 在作用于NHL和MM模型的高效性研究中, CUDC-907按最大耐受剂量处理,比单独药剂PI3K或HDAC抑制剂或两者联用效果更明显.且按最大耐受剂量处理,CUDC-907比PI3Kδ选择性抑制剂CAL-101更有效.CUDC-907对犬类具有口服生物有效性.CUDC-907在小鼠肿瘤中的半衰期较长.作用于移植瘤时,CUDC-907诱导凋亡并抑制癌细胞增殖.
体内活性: CUDC-907对一系列B细胞淋巴瘤的生长具有抑制作用,如Granta 519(IC50:7 nM),DOHH2(IC50:1 nM),RL(IC50:2 nM),Pfeiffer(IC50:4 nM),SuDHL4(IC50:3 nM),Daudi(IC50:15 nM) 和 Raji(IC50:9 nM)。CUDC-907对骨髓瘤增殖也有阻断作用,如RPMI8226(IC50:2 nM),OPM-2(IC50:1 nM)和ARH77(IC50:5 nM)。CUDC-907对多发性骨髓瘤和B细胞淋巴瘤均有明显抗癌活性。CUDC-907对其他PI3K亚型有抑制作用抑制,如 PI3Kβ/γ/δ和 PI3KαE545K, IC50分别为 54/311/39/62 nM。而且, CUDC-907对HDAC亚型HDAC8//6/11(IC50:191/27/5.4 nM)也有抑制效果。此外,CUDC-907对其他类型 HDAC 酶活性也有微弱抑制。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 94 mg/mL (184.8 mM)
关键字: CUDC907 | Fimepinostat | inhibit | HDAC | Inhibitor | Apoptosis | PI3K | Phosphoinositide 3-kinase | Histone deacetylases
相关产品: PR-619 | Anticancer agent 136 | Deoxypodophyllotoxin | Myristoleic acid | SCR7 | Isatuximab | Domatinostat tosylate | Lonicerin | Lorlatinib | Buparlisib
相关库: Drug Repurposing Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | DNA Damage & Repair Compound Library | Autophagy Compound Library | Reprogramming Compound Library
化合物CUDC-907 T2078信息由TargetMol中国为您提供,如您想了解更多关于化合物CUDC-907 T2078报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途